These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 8420192)

  • 21. Dystonia with marked diurnal variation associated with biopterin deficiency.
    Fink JK; Barton N; Cohen W; Lovenberg W; Burns RS; Hallett M
    Neurology; 1988 May; 38(5):707-11. PubMed ID: 2452381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Belly dystonia induced by levodopa and biperiden in a case of suspected multiple-system atrophy.
    Shan DE; Kwan SY; Ho HH; Su MS
    Mov Disord; 1996 Jul; 11(4):455-7. PubMed ID: 8813234
    [No Abstract]   [Full Text] [Related]  

  • 23. Portable device for quantifying parkinsonian wrist rigidity.
    Caligiuri MP
    Mov Disord; 1994 Jan; 9(1):57-63. PubMed ID: 7908119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease].
    Kreczy-Kleedorfer B; Wagner M; Bösch S; Poewe W
    Nervenarzt; 1993 Apr; 64(4):221-5. PubMed ID: 8506009
    [No Abstract]   [Full Text] [Related]  

  • 25. Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology.
    Poewe W; Lees AJ; Steiger D; Stern GM
    Adv Neurol; 1987; 45():357-60. PubMed ID: 3825711
    [No Abstract]   [Full Text] [Related]  

  • 26. Hereditary dystonia-parkinsonism syndrome of juvenile onset.
    Nygaard TG; Duvoisin RC
    Neurology; 1986 Nov; 36(11):1424-8. PubMed ID: 3762960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Segawa disease with a novel heterozygous mutation in exon 5 of the GCH-1 gene (E183K).
    Ikeda T; Kanmura K; Kodama Y; Sawada K; Nunoi H; Hasegawa K
    Brain Dev; 2009 Feb; 31(2):173-5. PubMed ID: 18621497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Peppe A; Dambrosia JM; Chase TN
    Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213
    [No Abstract]   [Full Text] [Related]  

  • 30. A clue to the pathogenesis of dopa-responsive dystonia.
    Furukawa Y; Mizuno Y; Nishi K; Narabayashi H
    Ann Neurol; 1995 Jan; 37(1):139-40. PubMed ID: 7818251
    [No Abstract]   [Full Text] [Related]  

  • 31. Vascular parkinsonism--an important update.
    Turnbull C
    Age Ageing; 2005 Mar; 34(2):97-8. PubMed ID: 15713851
    [No Abstract]   [Full Text] [Related]  

  • 32. GTP-cyclohydrolase I gene mutations in hereditary progressive amd dopa-responsive dystonia.
    Furukawa Y; Shimadzu M; Rajput AH; Shimizu Y; Tagawa T; Mori H; Yokochi M; Narabayashi H; Hornykiewicz O; Mizuno Y; Kish SJ
    Ann Neurol; 1996 May; 39(5):609-17. PubMed ID: 8619546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Square-wave action dystonia in Parkinson's disease.
    van den Munckhof P; Lenz FA; Chase TN
    Mov Disord; 1998 Mar; 13(2):354-6. PubMed ID: 9539355
    [No Abstract]   [Full Text] [Related]  

  • 35. Does fluoxetine aggravate Parkinson's disease? A pilot prospective study.
    Montastruc JL; Fabre N; Blin O; Senard JM; Rascol O; Rascol A
    Mov Disord; 1995 May; 10(3):355-7. PubMed ID: 7651460
    [No Abstract]   [Full Text] [Related]  

  • 36. Juvenile parkinsonism: ventricular CSF biopterin levels and clinical features.
    Furukawa Y; Nishi K; Kondo T; Mizuno Y; Narabayashi H
    J Neurol Sci; 1992 Apr; 108(2):207-13. PubMed ID: 1517754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of L-dopa on oculogyric crises in a case of dopa-responsive dystonia.
    Lamberti P; de Mari M; Iliceto G; Caldarola M; Serlenga L
    Mov Disord; 1993 Apr; 8(2):236-7. PubMed ID: 8474501
    [No Abstract]   [Full Text] [Related]  

  • 38. Concentrations of neopterin and biopterin in the cerebrospinal fluid of patients with Parkinson's disease.
    Fujishiro K; Hagihara M; Takahashi A; Nagatsu T
    Biochem Med Metab Biol; 1990 Oct; 44(2):97-100. PubMed ID: 2252621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.
    Poewe W; Kleedorfer B; Wagner M; Bösch S; Schelosky L
    Adv Neurol; 1993; 60():656-9. PubMed ID: 8420206
    [No Abstract]   [Full Text] [Related]  

  • 40. Dopa-responsive, nonprogressive juvenile parkinsonism: report of a case.
    Rajput A; Kishore A; Snow B; Bolton CF; Rajput AH
    Mov Disord; 1997 May; 12(3):453-6. PubMed ID: 9159748
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.